menu
    • menu

    Company profile for NextPoint

    NEW Drugs in Dev: 2
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precisio...
    NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NextPointUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://nextpointtx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NextPoint Therapeutics to Present Preclinical Data on NPX125
    NextPoint Therapeutics to Present Preclinical Data on NPX125

    25 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250425679992/en/NextPoint-Therapeutics-to-Showcase-Pioneering-Preclinical-Data-on-NPX125-a-Novel-B7-H7-Targeted-Antibody-Drug-Conjugate-ADC-at-AACR-Annual-Meeting-2025

    BUSINESSWIRE
    25 Apr 2025
    Share Share
    NextPoint Therapeutics to Present ADC & TCE Finding at AACR Meeting
    NextPoint Therapeutics to Present ADC & TCE Finding at AACR Meeting

    07 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250407625405/en/NextPoint-Therapeutics-to-Highlight-Antibody-Drug-Conjugate-ADC-and-T-Cell-Engager-TCE-Preclinical-Findings-Targeting-Novel-B7-H7-Pathway-at-AACR-Annual-Meeting

    BUSINESSWIRE
    07 Apr 2025
    Share Share
    NextPoint Presents B7-H7 Directed T Cell Engager at SITC 2024
    NextPoint Presents B7-H7 Directed T Cell Engager at SITC 2024

    07 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241107481801/en

    BUSINESSWIRE
    07 Nov 2024
    Share Share
    NextPoint Announces New Drug Candidate NPX372 in Solid Tumors
    NextPoint Announces New Drug Candidate NPX372 in Solid Tumors

    05 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240905425048/en

    BUSINESSWIRE
    05 Sep 2024
    Share Share
    NextPoint CEO Ivan Cheung On TIME100 Health List
    NextPoint CEO Ivan Cheung On TIME100 Health List

    06 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240501681639/en

    BUSINESSWIRE
    06 May 2024
    Share Share
    NextPoint Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267
    NextPoint Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267

    17 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230817532951/en

    BUSINESSWIRE
    17 Aug 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search